NuCana discontinues Phase II NuTide:323 colorectal cancer study
NuCana called the cancellation of the study, which followed a committee recommendation, a ‘disappointing’ and ‘unexpected outcome’.
30 August 2024
30 August 2024
NuCana called the cancellation of the study, which followed a committee recommendation, a ‘disappointing’ and ‘unexpected outcome’.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.